Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT04095364

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Sponsor: NRG Oncology

Conditions Low Grade Fallopian Tube Serous Adenocarcinoma Ovarian Low Grade Serous Adenocarcinoma Primary Peritoneal Low Grade Serous Adenocarcinoma Stage II Fallopian Tube Cancer AJCC v8 Stage II Ovarian Cancer AJCC v8 Stage II Primary Peritoneal Cancer AJCC v8 Stage III Fallopian Tube Cancer AJCC v8 Stage III Ovarian Cancer AJCC v8 Stage III Primary Peritoneal Cancer AJCC v8 Stage IV Fallopian Tube Cancer AJCC v8 Stage IV Ovarian Cancer AJCC v8 Stage IV Primary Peritoneal Cancer AJCC v8

Interventions Biopsy Procedure Biospecimen Collection Carboplatin Imaging Procedure Letrozole Paclitaxel

Updated 23 times since 2019 Last updated: Jan 12, 2026 Started: Sep 20, 2019 Primary completion: Feb 1, 2027 Completion: Feb 1, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Low Grade Fallopian Tube Serous Adenocarcinoma and Ovarian Low Grade Serous Adenocarcinoma, this trial is ongoing. The trial is conducted by NRG Oncology and has accumulated 23 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

23 versions recorded

Feb 2026 — Present [monthly]

Active Not Recruiting PHASE3
Nov 2025 — Feb 2026 [monthly]

Active Not Recruiting PHASE3
Sep 2025 — Nov 2025 [monthly]

Active Not Recruiting PHASE3
Jun 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Sep 2024 — Jun 2025 [monthly]

Recruiting PHASE3

▶ Show 18 earlier versions

Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE3
Dec 2023 — Jun 2024 [monthly]

Recruiting PHASE3
Oct 2023 — Dec 2023 [monthly]

Recruiting PHASE3
Dec 2022 — Oct 2023 [monthly]

Recruiting PHASE3
Sep 2022 — Dec 2022 [monthly]

Recruiting PHASE3
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE3
May 2022 — Jul 2022 [monthly]

Recruiting PHASE3
Mar 2022 — May 2022 [monthly]

Recruiting PHASE3
Feb 2022 — Mar 2022 [monthly]

Recruiting PHASE3
Dec 2021 — Feb 2022 [monthly]

Recruiting PHASE3
Nov 2021 — Dec 2021 [monthly]

Recruiting PHASE3
Oct 2021 — Nov 2021 [monthly]

Recruiting PHASE3
Sep 2021 — Oct 2021 [monthly]

Recruiting PHASE3
Feb 2021 — Sep 2021 [monthly]

Recruiting PHASE3
Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE3
Dec 2019 — Jan 2021 [monthly]

Recruiting PHASE3
Oct 2019 — Dec 2019 [monthly]

Recruiting PHASE3

First recorded

Sep 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NRG Oncology
National Cancer Institute (NCI)

Data source: NRG Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United States , Albany, United States , Albert Lea, United States , Albuquerque, United States , Allentown, United States , Alma, United States , Alpena, United States , Alton, United States , Altoona, United States , Ames, United States and 536 more locations